| |
| |
|
| Insider
Information: |
Levy Richard S |
| Relationship: |
|
| City: |
Wilmington |
| State: |
DE |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
67,001 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,098,656 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
67,001 |
|
|
| Total
Value |
$3,098,656 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 195.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Incyte Corp |
INCY |
EVP, Chief Drug Dev Of... |
2016-01-06 |
16,926 |
2010-03-15 |
0 |
Premium* |
|
|
Madrigal Pharmaceuticals Inc |
MDGL |
|
2024-04-01 |
10,298 |
2017-08-21 |
0 |
Premium* |
|
|
Protara Therapeutics, Inc |
TARA |
Director |
2020-01-10 |
31,000 |
2020-01-10 |
0 |
Premium* |
|
|
Kodiak Sciences Inc. |
KOD |
Director |
2020-03-20 |
1,000 |
2020-03-20 |
0 |
Premium* |
|
|
Kiniksa Pharmaceuticals, Ltd. |
KNSA |
|
2023-11-03 |
7,777 |
2023-06-29 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MDGL |
Madrigal Pharmaceuticals ... |
|
– • – |
2024-04-01 |
4 |
AS |
$255.90 |
$2,832,335 |
D/D |
(11,000) |
10,298 |
0 |
% |
|
| MDGL |
Madrigal Pharmaceuticals ... |
|
– • – |
2024-04-01 |
4 |
OE |
$7.36 |
$703,160 |
D/D |
11,000 |
21,298 |
0 |
- |
|
| KNSA |
Kiniksa Pharmaceuticals, ... |
|
– • – |
2023-11-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,777 |
7,777 |
0 |
- |
|
| KNSA |
Kiniksa Pharmaceuticals, ... |
|
– • – |
2023-06-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2023-01-17 |
4 |
OE |
$100.45 |
$2,316,844 |
D/D |
22,489 |
31,589 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2023-01-17 |
4 |
AS |
$285.28 |
$6,592,686 |
D/D |
(22,489) |
9,100 |
0 |
% |
|
| KOD |
Kodiak Sciences Inc. |
Director |
– • – |
2020-03-20 |
4 |
B |
$43.37 |
$44,330 |
D/D |
1,000 |
1,000 |
2.39 |
% |
|
| TARA |
Protara Therapeutics, Inc |
Director |
– • – |
2020-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
31,000 |
31,000 |
0 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2017-08-23 |
4 |
B |
$16.08 |
$32,236 |
D/D |
2,000 |
9,100 |
2.39 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2017-08-22 |
4 |
B |
$15.99 |
$57,209 |
D/D |
3,550 |
7,100 |
2.39 |
- |
|
| MDGL |
Madrigal Pharmaceuticals ... |
Director |
– • – |
2017-08-21 |
4 |
B |
$15.67 |
$56,358 |
D/D |
3,550 |
3,550 |
2.39 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2016-01-06 |
4 |
AS |
$101.86 |
$401,023 |
D/D |
(3,937) |
16,926 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2016-01-06 |
4 |
OE |
$18.32 |
$72,126 |
D/D |
3,937 |
20,863 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-12-07 |
4 |
AS |
$106.18 |
$418,031 |
D/D |
(3,937) |
16,926 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-12-07 |
4 |
OE |
$18.32 |
$72,126 |
D/D |
3,937 |
20,863 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-11-06 |
4 |
OE |
$18.32 |
$72,108 |
D/D |
3,936 |
20,862 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-11-06 |
4 |
AS |
$116.51 |
$458,583 |
D/D |
(3,936) |
16,926 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-10-06 |
4 |
AS |
$122.29 |
$481,456 |
D/D |
(3,937) |
16,926 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-10-06 |
4 |
OE |
$18.32 |
$72,126 |
D/D |
3,937 |
20,863 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-09-11 |
4 |
AS |
$130.00 |
$559,130 |
D/D |
(4,301) |
16,926 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-09-08 |
4 |
OE |
$18.32 |
$72,126 |
D/D |
3,937 |
25,164 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-09-08 |
4 |
AS |
$118.90 |
$468,109 |
D/D |
(3,937) |
21,227 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-08-06 |
4 |
AS |
$111.95 |
$440,635 |
D/D |
(3,936) |
21,227 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-08-06 |
4 |
OE |
$18.32 |
$72,108 |
D/D |
3,936 |
25,163 |
0 |
- |
|
| INCY |
Incyte Corp |
EVP, Chief Drug Dev Officer |
• – – |
2015-07-15 |
4 |
AS |
$120.00 |
$8,426,040 |
D/D |
(70,217) |
21,227 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
